Clinical Trial

Evaluating the Addition of OK-1 Weekly Paclitaxel in Patients With Endometrial Cancer

Name: Evaluating the Addition of OK-1 Weekly Paclitaxel in Patients With Endometrial Cancer — clinical trial record (NCT07737795)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate whether treatment with the investigational drug OK-1 in combination with paclitaxel can reduce tumor burden in patients with advanced or recurrent endometrial cancer (A/R-EC).

Trial Details

NCT Number	NCT07737795
Lead Sponsor	University of Oklahoma Collaborators: National Cancer Institute (NCI)
Conditions	Endometrial Cancer
Enrollment	66 participants
Start Date	2026-08
Primary Completion	2028-08 (estimated)
Study Completion	2029-08 (estimated)
Updated on ClinicalTrials.gov	2026-07-30